GS Group contributed to a series B round that pushed messenger RNA therapeutics and vaccine developer RVAC Medicines' overall funding to $140m.

Singapore-headquartered messenger RNA (mRNA) product developer RVAC Medicines closed a series B round of undisclosed size yesterday featuring conglomerate GS Group that lifted its overall funding to $140m.

Healthcare investment group CBC led the round, which was also backed by Singaporean state-owned investment firm Temasek’s Pavilion Capital vehicle and another Singaporean government entity, EDBI.

Founded in June 2021, RVAC is utilising its proprietary mRNA platform to create vaccines and medicines. It has a partnership in place with Canada-based Acuitas Therapeutics,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn